Morin improves urate excretion and kidney function through regulation of renal organic ion transporters in hyperuricemic mice

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 3, 2010, Pages 411-427

  Wang, Cai Ping ^a   Wang, Xing ^a   Zhang, Xian ^a   Shi, Yun Wei ^a   Liu, Lei ^a   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE TRANSPORTER 9; MESSENGER RNA; MORIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC CARNITINE TRANSPORTER 1; ORGANIC CARNITINE TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; UNCLASSIFIED DRUG; URATE TRANSPORTER 1; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DOWN REGULATION; DRUG ACTIVITY; HYPERURICEMIA; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY EXCRETION;

EID: 78650345393     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3q30h     Document Type: Article

References (59)

1. Chonchol M., Shlipak M. G., Katz R., Sarnak M. J., Newman A. B., Siscovick D. S., Kestenbaum B., Carney J. K., and Fried L. F. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis, 50: 239-247, 2007.
2. Dehghan A., van Hoek M., Sijbrands E. J. G., Hofman A., and Witteman J. C. M. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care, 31: 361-362, 2008.
3. Johnson R. J., Titte S., Cade J. R., Rideout B. A., and Oliver W. J. Uric acid, evolution and primitive cultures. Semin Nephrol, 25: 3-8, 2005.
4. Klein B. E. K., Klein R., and Lee K. E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care, 25: 1790-1794, 2002.
5. Choi H. K., Mount D. B., and Reginato A. M. Pathogenesis of gout. Ann Intern Med, 143: 499-516, 2005.
6. Hediger M. A., Johnson R. J., Miyazaki H., and Endou H. Molecular physiology of urate transport. Physiology, 20: 125-133, 2005.
7. Eraly S. A., Vallon V., Rieg T., Gangoiti J. A., Wikoff W. R., Siuzdak G., Barshop B. A., and Nigam S. K. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics, 33: 180-192, 2008.
8. Caulfield M. J., Munroe P. B., O'Neill D., Witkowska K., Charchar F. J., Doblado M., Evans S., Eyheramendy S., Onipinla A., Howard P., Shaw-Hawkins S., Dobson R. J., Wallace C., Newhouse S. J., Brown M., Connell J. M., Dominiczak A., Farrall M., Lathrop G. M., Samani N. J., Kumari M., Marmot M., Brunner E., Chambers J., Elliott P., Kooner J., Laan M., Org E., Veldre G., Viigimaa M., Cappuccio F. P., Ji C., Iacone R., Strazzullo P., Moley K. H., and Cheeseman C. SLC2A9 is a high-capacity urate transporter in humans. Plos Med, 5: 1509-1523, 2008.
9. Enomoto A., Kimura H., Chairoungdua A., Shigeta Y., Jutabha P., Cha S. H., Hosoyamada M., Takeda M., Sekine T., Igarashi T., Matsuo H., Kikuchi Y., Oda T., Ichida K., Hosoya T., Shimokata K., Niwa T., Kanai Y., and Endou H. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature, 417: 447-452, 2002.
10. Ichida K., Hosoyamada M., Kimura H., Takeda M., Utsunomiya Y., Hosoya T., and Endou H. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int, 63: 143-155, 2003.
11. Vitart V., Rudan I., Hayward C., Gray N. K., Floyd J., Palmer C. N., Knott S. A., Kolcic I., Polasek O., Graessler J., Wilson J. F., Marinaki A., Riches P. L., Shu X., Janicijevic B., Smolej-Narancic N., Gorgoni B., Morgan J., Campbell S., Biloglav Z., Barac-Lauc L., Pericic M., Klaric I. M., Zgaga L., Skaric-Juric T., Wild S. H., Richardson W. A., Hohenstein P., Kimber C. H., Tenesa A., Donnelly L. A., Fairbanks L. D., Aringer M., McKeigue P. M., Ralston S. H., Morris A. D., Rudan P., Hastie N. D., Campbell H., and Wright A. F. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet, 40: 437-442, 2008.
12. Matsuo H., Chiba T., Nagamori S., Nakayama A., Domoto H., Phetdee K., Wiriyasermkul P., Kikuchi Y., Oda T., Nishiyama J., Nakamura T., Morimoto Y., Kamakura K., Sakurai Y., Nonoyama S., Kanai Y., and Shinomiya N. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet, 83: 744-751, 2008.
13. Graessler J., Graessler A., Unger S., Kopprasch S., Tausche A. K., Kuhlisch E., and Schroeder H. E. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum, 54: 292-300, 2006.
14. Vazquez-Mellado J., Jimenez-Vaca A. L., Cuevas-Covarrubias S., Alvarado-Romano V., Pozo-Molina G., and Burgos-Vargas R. Molecular analysis of the SLC22A12 (URAT1) gene in patientswith primary gout. Rheumatology, 46: 215-219, 2007.
15. Nigam S. K., Bush K. T., and Bhatnagar V. Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat Clin Pract Nephr, 3: 443-448, 2007.
16. Habu Y., Yano I., Takeuchi A., Saito H., Okuda M., Fukatsu A., and Inui K. Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1 rOAT3 and rOCT2. Biochem Pharmacol, 66: 1107-1114, 2003.
17. Habu Y., Yano I., Okuda M., Fukatsu A., and Inui K. Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney. Biochem Pharmacol, 69: 993-999, 2005.
18. Iseki K., Oshiro S., Tozawa M., Iseki C., Ikemiya Y., and Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res, 24: 691-697, 2001.
19. Burckhardt G., and Wolff N. A. Structure of renal organic anion and cation transporters. Am J Physiol-Renal, 278: F853-F866, 2000.
20. Inui K., Masuda S., and Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int, 58: 944-958, 2000.
21. Dresser M. J., Leabman M. K., and Giacomini K. M. Transporters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters. J Pharm Sci, 90: 397-421, 2001.
22. Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M., Fukatsu A., Ogawa O., and Inui K. I. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol, 13: 866-874, 2002.
23. Ji L., Masuda S., Saito H., and Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int, 62: 514-524, 2002.
24. Grover B., Buckley D., Buckley A. R., and Cacini W. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther, 308: 949-956, 2004.
25. Tokuhiro S., Yamada R., Chang X. T., Suzuki A., Kochi Y., Sawada T., Suzuki M., Nagasaki M., Ohtsuki M., Ono M., Furukawa H., Nagashima M., Yoshino S., Mabuchi A., Sekine A., Saito S., Takahashi A., Tsunoda T., Nakamura Y., and Yamamoto K. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet, 35: 341-348, 2003.
26. Peltekova V. D., Wintle R. F., Rubin L. A., Amos C. I., Huang Q. Q., Gu X. J., Newman B., Van Oene M., Cescon D., Greenberg G., Griffiths A. M., St George-Hyslop P. H., and Siminovitch K. A. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet, 36: 471-475, 2004.
27. Glube N., Closs E., and Langguth P. OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1). Mol Pharm, 4: 160-168, 2007.
28. Schneider R., Sauvant C., Betz B., Otremba M., Fischer D., Holzinger H., Wanner C., Galle J., and Gekle M. Downregulation of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of para-aminohippurate after ischemic acute renal failure in rats. Am J Physiol-Renal, 292: F1599-F1605, 2007.
29. Sakurai Y., Motohashi H., Ueo H., Masuda S., Saito H., Okuda M., Mori N., Matsuura M., Doi T., Fukatsu A., Ogawa O., and Inui K. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res, 21: 61-67, 2004.
30. Harris M. D., Siegel L. B., and Alloway J. A. Gout and hyperuricemia. Am Fam Physician, 59: 925-934, 1999.
31. Schlesinger N. Management of acute and chronic gouty arthritis - Present state-of-the-art. Drugs, 64: 2399-2416, 2004.
32. Umpierrez A., Cuesta-Herranz J., Heras M. D., Lluch-Bernal M., Figueredo E., and Sastre J. Successful desensitization of a fixed drug eruption caused by allopurinol. J Allergy Clin Immun, 101: 286-287, 1998.
33. Bomalaski J. S., and Clark M. A. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Current Rheumatology Reports, Volume 6: 7, 2004.
34. Wang X., Wang C. P., Hu Q. H., Lv Y. Z., Zhang X., Ouyang Z., and Kong L. D. The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. J Ethnopharmacol, 128: 107-15, 2010.
35. Hu Q. H., Jiao R. Q., Wang X., Lv Y. Z., and Kong L. D. Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice. J Ethnopharmacol, 128: 685-692, 2010.
36. Mo S. F., Zhou F., Lv Y. Z., Hu Q. H., Zhang D. M., and Kong L. D. Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol Pharm Bull, 30: 1551-6, 2007.
37. Yu Z. F., Fong W. P., and Cheng C. H. K. The dual actions of morin (3,5,7,2 ',4 '-pentahydroxyflavone) as a hypouricemic agent: Uricosuric effect and xanthine oxidase inhibitory activity. J Pharmacol Exp Ther, 316: 169-175, 2006.
38. Yu Z. F., Fong W. P., and Cheng C. H. K. Morin (3,5,7,2 ',4 '-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. Drug Metab Dispos, 35: 981-986, 2007.
39. Hong S. S., Seo K., Lim S. C., and Han H. K. Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacol Res, 56: 468-473, 2007.
40. Lim S. C., Im Y. B., Bae C. S., Han S. I., Kim S. E., and Han H. K. Protective effect of morin on the imipenem-induced nephrotoxicity in rabbits. Arch Pharm Res, 31: 1060-1065, 2008.
41. Hosoyamada M., Ichida K., Enomoto A., Hosoya T., and Endou H. Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol, 15: 261-268, 2004.
42. Perez-Ruiz F., Calabozo M., Erauskin G. G., Ruibal A., and Herrero-Beites A. M. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthrit Rheum-Arthr, 47: 610-613, 2002.
43. Carroll J. J., Coburn H., Douglass R., and Babson A. L. Simplified alkaline phosphotungstate assay for uric acid in serum. Clin Chem, 17: 158, 1971.
44. Preitner F., Bonny O., Laverriere A., Rotman S., Firsov D., Da Costa A., Metref S., and Thorens B. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. P Natl Acad Sci USA, 106: 15501-15506, 2009.
45. Hu Q. H., Wang C. A., Li J. M., Zhang D. M., and Kong L. D. Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. Am J Physiol-Renal, 297: F1080-F1091, 2009.
46. Schmittgen T. D., Zakrajsek B. A., Mills A. G., Gorn V., Singer M. J., and Reed M. W. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: Comparison of endpoint and real-time methods. Anal Biochem, 285: 194-204, 2000.
47. Nakagawa T., Hu H. B., Zharikov S., Tuttle K. R., Short R. A., Glushakova O., Ouyang X., Feig D. I., Block E. R., Herrera-Acosta J., Patel J. M., and Johnson R. J. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol-Renal, 290: F625-F631, 2006.
48. Padang C., Muirden K. D., Schumacher H. R., Darmawan J., and Nasution A. R. Characteristics of chronic gout in Northern Sulawesi, Indonesia. J Rheumatol, 33: 1813-1817, 2006.
49. Simoni R. E., Gomes L. N. L. F., Scalco F. B., Oliveira C. P. H., Neto F. R. A., and de Oliveira M. L. C. Uric acid changes in urine and plasma: An effective tool in screening for purine inborn errorsof metabolism and other pathological conditions. J Inherit Metab Dis, 30: 295-309, 2007.
50. Anzai N., Kanai Y., and Endou H. New insights into renal transport of urate. Curr Opin Rheumatol, 19: 151-157, 2007.
51. Keembiyehetty C., Augustin R., Carayannopoulos M. O., Steer S., Manolescu A., Cheeseman C. I., and Moley K. H. Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes. Mol Endocrinol, 20: 686-697, 2006.
52. Hosoyamada M., Sekine T., Kanai Y., and Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol-Renal, 276: F122-F128, 1999.
53. Kakehi M., Koyabu N., Nakamura T., Uchiumi T., Kuwano M., Ohtani H., and Sawada Y. Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Bioph Res Co, 296: 644-650, 2002.
54. Tamai I., Yabuuchi H., Nezu J., Sai Y., Oku A., Shimane M., and Tsuji A. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. Febs Lett, 419: 107-111, 1997.
55. Lu K. M., Nishimori H., Nakamura Y., Shima K., and Kuwajima M. A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. Biochem Bioph Res Co, 252: 590-594, 1998.
56. Wu T. W., Zeng L. H., Wu J., and Fung K. P. Morina wood pigment that protects 3 types of human-cells in the cardiovascular-system against oxyradical damage. Biochem Pharmacol, 47: 1099-1103, 1994.
57. Cho Y. M., Onodera H., Ueda M., Imai T., and Hirose M. A 13-week subchronic toxicity study of dietary administered morin in F344 rats. Food Chem Toxicol, 44: 891-897, 2006.
58. Hanasaki Y., Ogawa S., and Fukui S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radical Bio Med, 16: 845-850, 1994.
59. Fang S. H., Hou Y. C., Chang W. C., Hsiu S. L., Chao P. D. L., and Chiang B. L. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci, 74: 743-756, 2003.